This segment focuses on the development of therapeutic candidates targeting the triggering receptor expressed on myeloid cells 2 (TREM2), a key receptor involved in microglial function. Vigil Neuroscience is developing both a human monoclonal antibody agonist, VGL101 (Iluzanebart), and an orally-available small molecule TREM2 agonist, VG-3927. Research and development activities include preclinical studies, Phase 1 and Phase 2 clinical trials, and manufacturing. The therapeutic area is focused on neurodegenerative diseases, including adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP) and Alzheimer's disease. The goal is to restore microglial vigilance and reduce neuroinflammation, potentially improving patient outcomes. Vigil has a license agreement with Amgen Inc. for commercial development. The market positioning is in the rapidly growing neurodegenerative disease market, with a focus on genetically defined subpopulations. Future opportunities include expanding the TREM2 agonist platform to other neurodegenerative diseases. Regulatory and clinical aspects involve FDA approval processes and clinical trial execution. Partnerships with Sanofi are in place to advance the development and commercialization of these therapies.